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ABSTRACT Metalloproteases from at least two Gram-nega-
tive organisms selectively hydrolyze the surface of human fixed
washed platelets. The protease-treated platelets lose their ability
to aggregate with bovine von Willebrand factor and human von
Willebrand factor plus ristocetin. The present study reports the
membrane glycoprotein alterations and loss of platelet function
that occur after incubation of fresh washed human platelets with
a purified protease produced by Serratia marcescens. The studies
were undertaken in order to examine, using the Serratia protease
as an enzymatic probe, the relationship between externally ori-
ented glycoproteins and two known aggregating agents, bovine von
Willebrand factor and thrombin. Platelet membrane glycopro-
teins were analyzed after discontinuous NaDodSOpolyacryl-
amide gel electrophoresis using both staining with periodic
acid-Schiff reagent and autoradiography of 3H-labeled platelets.
Both methods of detection demonstrated that at Serratia protease
concentrations above 0.6 jig/ml there was hydrolysis within 3 min
of a membrane glycoprotein (Mr 185,000) corresponding to GPIb
in control platelets. The loss of GPIb was accompanied by the
appearance in the platelet supernatant of a glycopeptide (Mr
156,000). Under reducing conditions, the hydrolyzed membrane
glycopeptide in the supernatant had a consistently faster migration
(Mr 149,000). Platelets treated with Serratia protease at concen-
trations sufficient to give maximal cleavage of GPIb were unre-
sponsive to bovine von Willebrand factor and did not aggregate
or release ['4C]serotonin at doses of von Willebrand factor up to
0.33 unit/ml. On the other hand, the response to bovine a-throm-
bin was only minimally impaired by treatment with Serratia pro-
tease. These results implicate GPIb in the response by platelets
to bovine von Willebrand factor but suggest that surface compo-
nents other than GPIb play a major role in the response by plate-
lets to thrombin.
The platelet responds to environmental stimuli with a series of
events mediated by surface components. Among these com-
ponents are a number of externally oriented proteins and gly-
coproteins that could serve the role ofspecific binding proteins
or receptors (1, 2). In certain platelet disorders there is a re-
lationship between altered platelet response and qualitative or
quantitative differences in one or more ofthe known membrane
glycoproteins (3-6).
When washed human platelets are suspended in buffers con-
taining no chelating agents and are treated with sonication,
freezing and thawing, or prolonged storage, they readily lose
a surface-associated glycoprotein called glycocalicin (7). Gly-
cocalicin is soluble in aqueous buffers, highly glycosylated, rich
in sialic acid, and composed of a single polypeptide chain with
a molecular weight (Mr) of about 150,000. Initial reports indi-
cated that this glycoprotein acted as both a potent inhibitor of
thrombin-induced platelet aggregation and the platelet recep-
tor for von Willebrand factor (vWF) (8-10).
Later studies, however, have presented a somewhat contra-
dictory view. By using either a receptor bioassay (11) or im-
munochemical techniques (12), the vWF-binding protein was
shown to be an integral membrane glycoprotein, probably
GPIb. * This membrane component bound strongly to phenyl-
Sepharose (15), demonstrating a hydrophobic region missing in
glycocalicin (6). On the other hand, immunochemical tech-
niques, lectin affinity, and determination of electrophoretic
mobility (2, 5, 12, 16) have suggested that glycocalicin and the
detergent-soluble membrane glycoprotein may share a partial
identity. In addition, platelets from patients with Bernard-Soulier
syndrome that lack or have an abnormal GPIb on their surface
do not respond to or bind vWF (17) and have a reduced number
of binding sites for thrombin (9).
All the data could be reconciled if soluble glycocalicin were
proteolytically derived from the heavily glycosylated surface-
oriented membrane glycoprotein GPIb. Because chelating
agents, such as EDTA, interfere with the loss of glycocalicin
from the surface of stored platelets, a Ca2+-dependent protease
normally found in platelets (18, 19) might be responsible for the
cleavage. One objection to this hypothesis is a report that pep-
tide maps of the GPIb material prepared from platelet mem-
branes by lectin affinity chromatography in cation-containing
buffers show no similarity to the peptide maps obtained by using
purified glycocalicin (20). In a more recent study, however, in
which buffers containing EDTA were used, great similarity was
found between the tryptic peptide maps of glycocalicin and
GPIb (21).
In the present study, we have utilized a highly selective bac-
terial protease to further examine the role ofGPIb in the platelet
response to thrombin and vWF. In previous studies, we showed
that certain Gram-negative organisms, particularly Serratia
marcescens and Pseudomonas aeruginosa, produce-extracellu-
lar metalloproteases that selectively attack the surface ofhuman
fixed washed platelets (22). Incubation of such platelets with
these proteases destroyed their ability to aggregate with bovine
vWF and with human vWF plus ristocetin. The purified Ser-
ratia protease cleaved the fixed washed platelet surface more
Abbreviations: vWF, vonWillebrand factor; PRP, platelet-rich plasma;
PAS, periodic acid-Schiff reagent.
* The terms "GPIb" and "GPV" correspond to the nomenclature rec-
ommended by Phillips and Agin for platelet surface glycoproteins (13).
Mosher and coworkers have described an alternative system of no-
menclature based on molecular weight of reduced platelet glycopro-
teins determined by polyacrylamide gel electrophoresis. In their no-
menclature GPIba is GP140 and GPV is GP68 (14).
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selectively than either chymotrypsin or trypsin did. However,
it was difficult to take advantage of this selectivity because
chemical crosslinking of surface components during formalde-
hyde fixation precluded precise identification by polyacryla-
mide gel electrophoresis ofthe hydrolyzed surface components.
This, and the fact that fixed platelets do not aggregate with
thrombin, prompted us to extend our previous studies to a sys-
tem employing fresh washed platelets in order to identify the
surface substrates for the Serratia protease and to examine the
effect ofselective proteolysis on platelet-thrombin interactions.
MATERIALS AND METHODS
Reagents. Water was deionized and distilled in glass. All
chemicals were reagent grade unless otherwise specified. Tri-
tiated sodium borohydride, 5-15 Ci/mol (1 Ci = 3.7 X 1010
becquerels), was obtained from Research Products Interna-
tional (Kankakee, IL), and was dissolved in 1 mM NaGH. Neur-
aminidase (Vibrio cholerae), devoid of proteolytic activity, was
purchased from Schwarz/Mann. Galactose oxidase from Wor-
thington was further purified by gel chromatography on Seph-
arose 6B (Pharmacia). Aquasol-2 and ['4C]serotonin were ob-
tained from New England Nuclear. Serratia protease was a gift
from Arnold Kreeger (Bowman Gray School of Medicine, Win-
ston-Salem, NC). The highly purified protease was free ofphos-
pholipase C, deoxyribonuclease, lipase, elastase, hexapepti-
dase, collagenase, and alkaline phosphatase activities. Thrombin
was bovine a-thrombin, 3000 NIH units/mg, kindly supplied
by Roger L. Lundblad (University of North Carolina, Chapel
Hill, NC).
Washed platelets were obtained from normal healthy male
or female adult volunteer donors with no evidence of liver or
hematological disease and no exposure to aspirin-like drugs or
medications for at least 2 weeks prior to venipuncture. Informed
consent was obtained in accordance with the Helsinki Decla-
ration. The blood was drawn into citric acid/citrate/dextrose
(ACD) by the two-syringe 'technique and platelet-rich plasma
(PRP) was prepared by centrifugation at 100 X g for 20 min at
room temperature. The PRP was then pelleted and the platelet
pellet was washed with citrate/saline/glucose buffer by differ-
ential centrifugation. In. another procedure, the PRP was lay-
ered onto a plastic column containing Sepharose 2B (Pharmacia)
previously equilibrated with divalent cation-deficient Tyrode's
solution (pH 7.4) containing 1 mM EDTA. The column was
developed by using the same buffer, and the gel-filtered plate-
lets (2-4 x 108 per ml) were collected.
Fresh Washed Platelet Aggregability. Aggregability was as-
sayed at 37C with constant stirring at 1100 rpm in a dual-chan-
nel aggregometer from Payton (Buffalo, NY). The slope of the
aggregation response was calculated from the steepest part of
the aggregation curve. In the test system, fresh, washed,
['4C]serotonin-labeled platelets were treated with Serratia pro-
tease as described. Appropriate concentrations of bovine vWF
or thrombin were added and the slope of the aggregation re-
sponse was calculated and compared to that obtained with the
same initial platelet preparation treated in an identical fashion
with buffer.
Preparation and Treatment of 3H-Labeled Fresh Washed
Platelets. Proteins on the surface of gel-filtered platelets were
labeled by the galactose oxidase technique (13). 3H-Labeled
platelets were suspended in 2 ml of divalent cation-deficient
'Tyrode's solution (2-4 X 106 per,ul, 20.8 Aglul, 0.004 cpm per
platelet). In preparation for enzymatic digestion with Serratia
protease, 75 ul of labeled platelets was added to 825 JAd of di-
valent cation-deficient Tyrode's buffer warmed to 3rC. Ser-
ratia protease 100 /ul, was added to give final concentrations
of 0.6-20 tug/ml and the mixture was incubated for 3 min. The
treated platelets were pelleted in a Beckman Microfuge B for
60 sec. The supernatant was carefully removed and prepared
for polyacrylamide gel electrophoresis by the addition of-an-
equal volume of sample buffer (4). The pellet was resuspended
in 80 /.d ofTyrode's buffer, sonicated, and mixed with an equal
volume of sample buffer. Both sets of samples were boiled for
3 min after addition of sample buffer.
One-Dimensional NaDodSO4Polyacrylamide Gel Elec-
trophoresis. Electrophoresis was performed in 7.5% polyacryl-
amide, according to the technique of Laemmli (23). Gels were
stained sequentially with periodicacid-Schiffreagent (PAS) and
0.1% Coomassie brilliant'blue in 50% trichloroacetic acid. The
gels were subsequently equilibrated with 2,5-diphenyloxazole,
dried, and exposed to x-ray'film at - 700C (24). PAS-stained gels
and autoradiographs were scanned with a laser densitometer.
Preparation and Treatment of ['4C]Serotonin-Labeled
Fresh Washed Platelets. Whole blood was drawn as previously
described and PRP was 'prepared by centrifugation at 460 X g
for 8 min at 230C. Incorporation of label by the platelets was
effected by adding 0.5 1ul of [14C]serotonin (specific activity,
47.2 mCi/mmol) per ml of PRP and incubating the mixture at
370C for 30 min.
After incubation, the platelets were pelleted by centrifuga-
tion at 860 x g for 8 min at 230C. The platelet pellet was re-
suspended in citrate/saline buffer and washed three times. The
labeled platelets were adjusted to a final count of 8 X 105 per
ttl using a Thrombocounter C (Coulter).
Serotonin release was quantitated by methods previously
reported (4). Equal volumes of [14C]serotonin-labeled fresh
washed platelets were mixed with Serratia protease or buffer
and incubated for 15 min at 230C. After incubation, 0.4 ml of
the mixture was added to a glass cuvette and aggregation was
initiated by adding dilutions of bovine plasma or thrombin.
RESULTS
Effect of Serratia Protease on Platelet Surface Components.
Fresh human platelets labeled with 3H were incubated with
increasing concentrations of Serratia protease and the digested
platelets were pelleted. The Serratia protease-treated pellets
and their corresponding supernatants were electrophoresed on
NaDodSO4/polyacrylamide gels under both reducing and non-
reducing conditions. The gels were analyzed for proteins and
glycoproteins by both conventional PAS and Coomassie staining
and autoradiography. Fig. 1 shows representative densitometric
scans of the PAS-stained unreduced gels of the platelet pellets
obtained after incubation with Serratia protease at final con-
centrations ranging between 0.6 and'20pug/ml. At 0.6 ttg/ml,
the residual glycoproteins gave a pattern indistinguishable from
,that obtained with the control platelets. However, above 0.6
pug/ml, the unreduced gels of the Serratia protease-treated
platelet pellets showed a significant reduction in a PAS-positive
band of approximately 185,000 'molecular weight. This band
corresponded to GPIb in the conventional gel pattern obtained
with control platelets. Similarly, in the reduced gels of the pel-
lets, there was a decrease in a single PAS-staining band with
an estimated molecular weight of 155,000.
Similar results were obtained from the analysis of the auto-
radiograms. Again, increasing concentrations of. Serratia pro-
tease resulted in the loss of a radiolabeled protein (Fig. 2) that
comigrated with the PAS-positive band that was shown to dis-
appear in the same gels stained for carbohydrate (Fig. 1). At
'10-20 pug/ml of Serratia protease there was a slight but con-
sistent reduction in at least one other labeled band (GPIa) as
determined by autoradiography. There was no obvious reduc-
tion in GPV.
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FIG. 1. Densitometric scans of samples of Serratia protease-treated
platelet pellets electrophoresed unreduced on one-dimensional
NaDodSO4/7.5% polyacrylamide- gels and stained for carbohydrate.
Fresh washed gel-filtered platelets (75 ,ul at 2-4 x 106/,ul), 825 ,ul of
divalent cation-deficient Tyrode's buffer, and 100 jul of Serratia pro-
tease to give final /Ag/ml concentrations of 0.6 (A), 1.25 (B), 2.5 (C),
5.0 (D), 10.0 (E), and 20.0 (F) were mixed and incubated for 3 min at
370C.
When the reduced and unreduced gels were stained for pro-
tein and densitometric scans ofthe stained gels were compared,
no significant differences were observed.
The NaDodSOIpolyacrylamidegels of the supernatants











was detected by both PAS staining and autoradiography. The
band had a molecular weight on unreduced gels of-approxi-
mately 156,000 and on reduced gels of approximately 149,000.-
The amount of this material in the supernatant, as determined
by densitometric scans of the gels stained for PAS and then
developed as autoradiographs, increased when increased con-
centrations of Serratia protease were used in the original in-
cubation mixture.
Effect of Serratia Protease on Platelet Function. Fresh,
washed, [14C]serotonin-labeled platelets were incubated with
Serratia protease at a final concentration of 5 tug/ml. At this
concentration, with most of the GPIb cleaved from the surface
(Fig. 1), Serratia protease did not cause platelet aggregation or
the release of ['4C]serotonin. These Serratia protease-treated
platelets were compared with untreated platelets for their re-
sponse to bovine vWF and thrombin. Bovine vWF, even at 0.33
unit/ml, caused neither ['4G]serotonin release nor aggregation
of Serratia protease-treated platelets (Fig. 3). In the control
system, it can be noted that at low concentrations ofvWF, 0.02
unit/ml, there was measurable platelet aggregation with no
evidence of appreciable ['4C]serotonin release.
Similar experiments using thrombin are shown in Fig. 4.
Serratia protease-treated platelets that were unresponsive to
vWF would both release and aggregate with thrombin. How-
ever, the Serratia protease-treated platelets required about two
times the concentration of thrombin to obtain the same degree
of release and about four times the concentration of thrombin
to obtain the same rate of aggregation as untreated platelets.
At a thrombin concentration of 0.1 unit/ml, the Serratia pro-

























FIG. 2. Effect of Serratia protease on platelet surface proteins
studied by autoradiography. Gel-filtered platelets were labeled by the
neuraminidase-galactose oxidase-NaB H4 method and incubated
with Serratia protease for 3 min at 3700. The platelets were then cen-
trifugedand the pelletswere prepared for electrophoresis in 7.5% acryl-
amide gels. The gels were prepared for autoradiography and then ex-
posed to film for 72 hours at -70°C. The final concentrations, of
Serratia protease in ,ug/ml were. 0.6 (lane 1), 1.2 (lane 2), 2.5 (lane 3),
5.0 (lane 4), 10 (lane 5), and 20 (lane 6).
0.03 0.05 0.1
Bovine vWF, units/ml
FIG.. 3. Effect of various concentrations of bovine vWF on [14C]_
serotonin-labeled fresh washed platelets incubated with buffer (0) or
with a final concentration of Serratia protease of 5 mg/ml (o) for 15
min at 23°C. Control or Serratia protease-treated labeled platelets
were adjusted to 8 x 10r per ,u and monitored for rate of aggregation
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FIG. 4. Effect of various concentrations of bovine a-thrombin on
['4C]serotonin-labeled fresh washed platelets incubated with buffer
(i) or with Serratia protease at a final concentration of 5 pg/ml (0)
for 15 min at 230C. Control or Serratia protease-treated platelets were
adjusted to 8 X 105 per gl and monitored for rate of aggregation (A)
and ["4C]serotonin release (B).
DISCUSSION
The present studies indicate that the interaction of a purified
metalloprotease from Serratia marcescens with human platelet
membranes is highly specific over a range of concentrations.
This specificity has been used to further probe the relationship
of bovine vWF and thrombin with receptor or binding com-
ponents in the membrane of human platelets.
The membrane glycoprotein pattern obtained by Na-
DodSO,/polyacrylamide gel electrophoresis of platelet pellets
treated with Serratia protease showed a progressive decrease
and eventual disappearance of the major membrane glycopro-
tein that in gels with nonreducing conditions had a molecular
weight of 185,000 (Fig. 1) and in gels with reducing conditions
had a molecular weight of 155,000. This was confirmed by using
autoradiography, in which the major radiolabeled protein that
was cleaved comigrated with the PAS-stained band, which in
both systems exhibited mobility before and after reduction con-
sistent with GPIb. The loss of this glycoprotein was almost com-
plete after incubation of human platelets with a final Serratia
protease concentration of 5.0 ,ug/ml (Fig. 1). The loss of GPIb
from the surface was accompanied by the appearance in the
corresponding platelet supernatant of a. labeled 156,000-dalton
glycopeptide (unreduced gels).
The reduction of GPIb on the platelet surface was associated
with a.complete loss of the ability of the platelet to release
['4C]serotonin or to aggregate in the presence of bovine vWF.
These observations suggest that the portion ofGPIb hydrolyzed
by Serratia protease is intimately involved in the interaction
ofvWF with the platelet surface. Previous studies showed that
the fragment cleaved by Serratia protease from fixed washed
platelets (22) could not act as a competitive inhibitor in the ag-
gregation of platelets with bovine vWF. Although failure to
demonstrate blocking activity in the Serratia protease super-
natant precludes the assignment ofreceptor or binding function
to the fragment from fixed platelets, it does not prevent the
assignment of these functions to GPIb. In addition, the inter-
action ofvWF with a receptor on the platelet surface could re-
quire more than one GPIb molecule or GPIb and one or more
additional membrane components (lipid or protein). The latter
concept is consistent with our previous observations that re-
ceptor activity is altered after selective solubilization ofplatelet
membranes with nonionic detergents (11). Alternatively, native
GPIb, including the Serratia protease cleavage product, may
have a different conformation on the platelet surface than it has
when liberated in solution by detergent or enzyme and may
therefore be less reactive toward vWF.
It is interesting to compare the effect of Serratia protease on
GPIb with the known effects of other proteases on platelet
membrane glycoproteins. GPIb is a two-chain molecule com-
posed ofa large molecularweight subunit, GPIba,. that contains
most ofthe carbohydrate and a smaller subunit, GPIbp3. Trypsin
cleaves a macroglycopeptide (Mr 120,000) from the surface of
intact platelets (25) that is immunologically and analytically
identical with a macroglycopeptide cleaved from- glycocalicin
by trypsin (6). The remaining peptide tail of the glycocalicin
molecule (Mr 45,000) is practically devoid of carbohydrate and
has no known hydrophobic domain. A calcium-activated pro-
tease has been shown to liberate the 148,000-dalton fragment,
glycocalicin, from human platelets (26). These datasuggest that
the cleavage site on GPIb for calcium-activated protease is
closer to the site ofinsertion in the membrane than is the cleav-
age site for trypsin. It is not yet clear whether there is a cleavage
site for Serratia protease in one or both chains of GPIb.
On reduction, the PAS-positive band observed in the super-
natant had an electrophoretic mobility that was essentially the
same as that of glycocalicin. Although there was a consistently
increased electrophoretic mobility of the Serratia protease-
cleaved product on 7.5% gels after reduction, the differences
were so small that we were unable. to conclude whether or not
this represented the reduction ofan interchain disuffide bond.
As mentioned before, early attempts to study the role of
membrane glycoproteins in platelet function produced data
suggesting that the soluble glycoprotein, glycocalicin, was the
surface receptor for both vWF and thrombin (8-10). The por-
tion of the GPIb molecule purported to be the thrombin re-
ceptor is the 45,000-dalton peptide "tail" of glycocalicin (6). In
the present study, the functional interaction of thrombin with
platelets was relatively intact despite..enzymatic removal by
Serratia protease ofmost ofthe exposed GPIb from the platelet
surface, and it would appear that the 156,000-dalton fragment
removed does not play an essential role in the response ofplate-
lets to thrombin. Nevertheless, the response of Serratia pro-
tease-treated platelets to thrombin was not entirely normal.
Thus, GPIb may modulate the-response of platelets to throm-
bin. Tam and coworkers previously showed that chymotrypsin,
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response by platelets to thrombin, suggesting that chymotryp-
sin-sensitive components on the platelet surface were involved
in the postbinding receptor processing that leads to generation
of a stimulatory signal (27). The specificity of Serratia protease
suggests that the chymotrypsin-sensitive component may be
GPIb. On the other hand, removal of this product abolishes the
vWF-platelet interaction. This is also further indirect support
for the role of GPIb as the receptor for vWF, because not only
bovine vWF aggregation but also bovine vWF-induced platelet
release is inhibited.
Recent observations have indicated a possible relationship
between GPIb and another platelet membrane glycoprotein,
GPV, which is a known substrate for thrombin on the platelet
surface (13, 14). Like GPIb, GPV is eluted or released from the
platelet surface under certain conditions (14) or by prolonged
storage (28). In addition, GPIb and GPV are both reduced in
isolated membrane preparations from normal platelets (28), and
clinical studies in patients with Bernard-Soulier syndrome in-
dicate that both GPIb and GPV are missing on the surface of
whole platelets from patients with this disorder (29, 30). How-
ever, platelets treated with Serratia protease at concentrations
that cleave GPIb retain GPV on the cell surface (Fig. 2), indi-
cating that, at least under certain conditions, GPIb and GPV
may not be associated on the platelet surface or that the asso-
ciation between GPIb and GPV is not mediated by the portion
ofGPIb cleaved by Serratia protease. Although it is not evident
from our experiments, it is possible that some GPV is lost and
that the small reduction in GPV might contribute to the de-
creased response of Serratia protease-treated platelets to
thrombin.
It is of interest that the hydrolysis of some membrane com-
ponents may stimulate platelets, whereas known proteases that
appear to more or less selectively cleave GPIb alone (Serratia
protease, the calcium-activated protease, and chymotrypsin) do
not. Future studies utilizing enzymes with known differences
in membrane substrate specificity should be helpful in further
understanding the relationships among GPIb, GPV, and their
fuinctional ligands.
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